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ABSTRACT 27 
Purpose: Women with polycystic ovary syndrome (PCOS) exhibit many metabolic 28 
abnormalities that are associated with an increased cardiovascular disease risk. Exercise may 29 
promote improvements in lipid profile and insulin sensitivity in women with PCOS. There is 30 
however, a knowledge gap on the optimal dose of exercise, regarding duration, intensity, 31 
type, and frequency of exercise. The aim of this systematic review and meta-analysis was to 32 
define effective types of exercise to improve cardiometabolic profile in PCOS.  33 
Methods: We included randomised controlled trials (RCT), quasi-RCT, and controlled 34 
clinical trials focusing on reproductive-aged women diagnosed with PCOS. Eligible 35 
interventions included those with at least two weeks of supervised exercise sessions. Primary 36 
outcomes were blood lipids, blood glucose, blood pressure, measures of abdominal adiposity, 37 
and inflammation markers. Secondary outcomes were total and free testosterone, sex 38 
hormone binding globulin, and measures of insulin resistance. Nine electronic databases were 39 
searched from inception to present for English language publications. The Cochrane Risk 40 
Assessment tool was used to assess bias in the included studies. Outcomes were 41 
quantitatively synthesised and a meta- analysis was performed. Pooled effect estimates and 42 
95% confidence intervals were presented.  43 
Results: This systematic review identified three trials, including 231 participants with PCOS that 44 
examined the effect of structured, supervised exercise on cardiometabolic outcomes. Analysis of 45 
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pooled data indicated statistical favourable effects of exercise on total cholesterol, fasting glucose, 46 
waist circumference and waist-to-hip ratio, systolic blood pressure, C-reactive protein, total 47 
testosterone, and sex hormone binding globulin using post-intervention scores.  48 
Conclusions: Moderate aerobic exercise interventions ≥3 months in duration, with a frequency of 49 
3/week for at least 30-minutes, may have favourable effects on various cardiometabolic risk factors in 50 
women with PCOS. However, results should be interpreted with caution. Many of the outcomes were 51 
based on studies with serious methodological limitations, and only one "gold-standard" RCT was 52 
identified.  53 
PROSPERO ID: CRD42018086117 54 
Keywords 55 
polycystic ovary syndrome, exercise, cardiovascular disease, metabolism 56 
 57 
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BACKGROUND 77 
Polycystic ovary syndrome (PCOS) is a common complex hormonal and metabolic condition 78 
[1]. The now internationally accepted Rotterdam Criteria, derived by the European Society of 79 
Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive 80 
Medicine (ASRM), requires that women present with at least two of the three 81 
signs/symptoms (clinical or biochemical hyperandrogenism, anovulation or oligomenorrhea, 82 
and polycystic ovaries) to receive a diagnosis, in the absence of other pathologies that can 83 
promote these symptoms [2].  84 
 85 
The metabolic complications associated with an increased cardiovascular disease (CVD) risk 86 
in PCOS, independent of obesity [3], include insulin resistance, impaired glucose tolerance 87 
(IGT), dyslipidemia, type 2 diabetes (T2D), hypertension, subclinical atherosclerosis, and a 88 
two to four-fold higher prevalence of metabolic syndrome compared to body mass index 89 
(BMI)-matched women [4, 5, 6, 7]. Dyslipidemia, characterised by high triglyceride (TG) 90 
and low high-density lipoprotein (HDL) concentrations, is prevalent in up to 70% of women 91 
with PCOS [5].  92 
Inflammatory markers that are implicated in the mediation of CVD may be elevated in 93 
women with PCOS [8]. These markers range from high-sensitivity C-reactive protein [9, 10] 94 
to increased white cell count, neutrophil/lymphocyte ratio, tumour-necrosis factor-alpha 95 
5 
 
(TNF-a) and interleukin-6 (IL-6) [10, 11, 12, 13]. Moreover, a 2012 review indicates that 96 
various studies have reported that carotid intima-media thickness (cIMT), a marker of 97 
subclinical atherosclerosis, is higher in women with PCOS in comparison to controls [14]. 98 
Hyperandrogenism is associated with hyperinsulinemic states because insulin has the 99 
capacity to act as a co-gonadotrophin, thus stimulating ovarian androgen production  [15]. 100 
The increased circulating androgens may then contribute to inflammation by promoting 101 
adipocyte hypertrophy and stimulating mononuclear cells to release TNF-a and IL-6 [16]. In 102 
addition, hyperandrogenism may then promote abdominal fat accumulation and further 103 
exacerbate insulin resistance. Phenotypes that present with hyperandrogenism may therefore 104 
have a worse metabolic profile despite comparable distributions of body weight [17, 18].  105 
Lifestyle interventions and modifications are widely considered to be a cornerstone of PCOS 106 
treatment for cardiometabolic symptoms [19, 20]. Exercise interventions in PCOS have 107 
promoted improvements in lipid profile, ovulation, and insulin sensitivity by up to 30% in 108 
women with PCOS, independent of weight loss, within 12 weeks [21]. This indicates that the 109 
increased CVD risk factors associated with PCOS are not solely attributed to obesity, and 110 
lean women with PCOS can still benefit from exercise to improve their cardiometabolic 111 
profile.   112 
There currently lacks guidance on which exercise interventions are effective for differing 113 
phenotypes, regarding duration, type of exercise and frequency of exercise sessions. 114 
Subsequently, the objective of this systematic review and meta-analysis is to define regimes 115 
of exercise interventions, which could improve the cardiometabolic profile across a range of 116 
phenotypes of PCOS. 117 
 118 
METHODS 119 
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The review is reported in accordance with the Preferred Reporting Items for Systematic 120 
Reviews and Meta-Analysis (PRISMA) guidelines and was pre-registered in the International 121 
Prospective Register of Systematic Reviews (PROSPERO): CRD42018086117. The full 122 
protocol is described elsewhere [22]. 123 
Eligibility Criteria 124 
Randomised-controlled Trials (RCT), quasi-RCT, and clinical trials were screened according 125 
to Population, Intervention, Comparison and Outcome (PICO) criteria: participants were 126 
reproductive aged women diagnosed with PCOS according to Rotterdam Criteria 2003 [23], 127 
National Institute of Health (NIH) 1990 criteria [24], or Androgen Excess and Polycystic 128 
Ovary Syndrome (AE-PCOS) Society 2006 criteria [25]. They were excluded if they were 129 
undergoing fertility treatment, taking metformin or OCP, undertaking regular exercise 130 
training, or had a diagnosis of any pathology that may be promoting PCOS symptoms. 131 
The intervention could encompass aerobic exercise training, anaerobic exercise training, 132 
resistance training, or combinations, of at least two weeks in duration of structured, 133 
supervised sessions only. Sessions could be conducted in any setting, as groups or 134 
individuals. Crossover trials and interventions that were combined (such as a lifestyle 135 
intervention including both exercise and diet management) were excluded. Studies had to 136 
include a control group of women with PCOS undertaking no interventions. 137 
Outcomes must have been measured pre-intervention and immediately post-intervention. 138 
Primary outcomes identified included low-density lipoprotein cholesterol (LDL-C), high-139 
density lipoprotein cholesterol (HDL-C), total cholesterol (TC), TC:HDL ratio, TG, oxidised 140 
LDL, cIMT, fasting blood glucose, HbA1c, blood pressure, waist circumference (WC), waist-141 
to-hip ratio (WHR), abdominal adiposity and any inflammation markers.  142 
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Secondary outcomes included total testosterone, free testosterone, sex hormone binding 143 
globulin (SHBG), fasting insulin, and homeostatic model assessment for insulin resistance 144 
(HOMA-IR).  145 
Searches 146 
The electronic databases as follows were searched from inception to present: CINAHL 147 
Complete (EBSCO), Cochrane Central Register of Controlled Trials (CENTRAL) (Wiley), 148 
MEDLINE (EBSCO), Scopus (Elsevier), SPORTDiscus (EBSCO), PEDro (The University of 149 
Sydney), PubMed (US National Library of Medicine), ClinicalTrials.gov and UK Clinical 150 
Trials Gateway. Only English language publications were sought. Search terms used were 151 
PCOS or polycystic ovary syndrome and terms relating to exercise or physical activity 152 
interventions. These were adapted for use with all databases; the PubMed search strategy can 153 
be found in Online Resource 1. 154 
Online Resource 1. PubMed Search Strategy. 155 
Data Collection and Analysis 156 
Study Selection 157 
Results from the database searches were imported into RefWorks (ProQuest) and duplicate 158 
records were removed. Screening was undertaken in Microsoft Excel (version 16.0). At title 159 
and abstract screening phase one reviewer (AW) screened all studies, with a second reviewer 160 
screening all in duplicate (MK and DRB). 161 
The full-text of the remaining studies were screened by AW to determine their eligibility for 162 
inclusion in the review, with each study checked independently by a second reviewer (MK or 163 
DRB).  Reasons for exclusion were recorded. Throughout all stages, disagreement between 164 
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two reviewers was resolved by discussion and input from a third reviewer until a consensus 165 
was reached.  166 
 167 
Data Extraction 168 
An a priori data extraction form was created in Microsoft Excel (version 16.0). AW extracted 169 
all data using the form, with MK and DRB each independently checking all data for 170 
consistency. Extracted data included bibliographic information, study characteristics, 171 
participant characteristics, intervention and comparison data including adherence and attrition 172 
rates, and outcome data including any relevant parameters named in the primary and 173 
secondary outcomes. In the case of any missing or unclear data, two attempts were made to 174 
contact the corresponding author by email. If no response was received, the missing data was 175 
not included in the meta-analysis. 176 
 177 
Risk of Bias in Individual Studies & Heterogeneity 178 
The Cochrane Risk of Bias Assessment tool [26] was used to assess quality at the study level 179 
as high, low, or unclear risk of biasThe tool evaluates studies based on seven criteria: 1) 180 
randomisation generation, 2) allocation concealment, 3) blinding of outcome assessors, 4) 181 
blinding patients/study personnel, 5) incomplete outcome data (that is, lost to follow-up), 6) 182 
selective outcome reporting, and 7) other risks of bias. 183 
Heterogeneity of results was assessed using the I² statistic. This statistic was chosen for its 184 
simplicity and applicability to meta-analyses regardless of the number of studies involved as 185 
described in the literature [27]. It describes the variability, presented as a percentage, in effect 186 
estimates that is due to heterogeneity rather than sampling error and its interpreted as follows: 187 
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0-40%: might not be important, 30-60%: may represent moderate heterogeneity, 50-90%: 188 
may represent substantial heterogeneity, and 75-100%: considerable heterogeneity A result of 189 
over 50% was considered significant heterogeneity [28]. Sensitivity analyses were performed 190 
as appropriate by removing studies with small sample sizes (<30) or those with a high risk of 191 
selection bias. 192 
Data Synthesis 193 
Outcomes measured and presented pre and post intervention were quantitatively synthesised 194 
and analysed using RevMan 5 [29]. The  I²  statistic, as well as considering clinical and 195 
methodological heterogeneity, was used to determine whether random-effects or fixed-effects 196 
meta-analysis was used.  Forest plots were generated where a P-value of <0.05 was 197 
considered statistically significant. Each outcome for each study was recorded with mean and 198 
standard deviation (SD) of each group, effect size (difference between means), 95% 199 
confidence intervals (CI), and study weighting. Pooled mean difference, 95% CI, P-values 200 
and I² statistic were also recorded for each outcome. 201 
Confidence in findings 202 
The Grading of Recommendations Assessment, Development and Evaluation (GRADE) was 203 
used to grade the quality of the evidence and the strength of each finding [30]. GRADE uses 204 
a scoring system (very low, low, moderate, high) to grade each finding in several areas 205 
including limitations, consistency, directness, and publication bias. The use of a consistent 206 
and transparent approach to evaluating recommendations increases the facilitation of critical 207 
appraisal and improves communication of these judgments [30]. 208 
 209 
RESULTS 210 
Results of the Search 211 
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The initial search of databases identified a combined total of 2,334 records. Once duplicates 212 
were removed, 2,163 records remained for title and abstract screening. Records were 213 
excluded (n = 2,136) because the title and abstract screening revealed that the articles did not 214 
meet the inclusion criteria. Twenty-seven articles were selected for full-text eligibility 215 
screening. Twenty-four were excluded for the reasons identified in Fig 1. 216 
Fig 1 PRISMA flow-chart 217 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting 218 
Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): 219 
e1000097. doi:10.1371/journal.pmed100009 220 
 221 
Study Design and Data Handling 222 
Three studies were included in the meta-analysis. One was an exercise only RCT [31] and 223 
two were exercise only non-randomised clinical trials [32, 33] All compared an exercise 224 
intervention to a control group or standard care. 225 
Two studies presented data as mean and SD [31, 32], and one presented data as mean and 226 
95% CI[33]. Data from the latter study were converted into mean and SD. Data were 227 
converted into the most common unit used for each variable if there were discrepancies 228 
Sensitivity analysis was performed either by removing studies with small sample sizes (<30 229 
participants) from the pooled data or by removing those with a high risk of selection bias. 230 
Participant Characteristics 231 
Table 1 is a summary of characteristics of the three included studies.  Across all studies, there 232 
was a total of 231 participants, with 117 receiving an exercise intervention and 114 controls. 233 
Total participants ranged from 124 [32] to 17 [33]. The 2003 Rotterdam criteria  was used to 234 
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reach a PCOS diagnosis in all three studies [31, 32, 33]. The mean age of participants was 26 235 
years, ranging from 22  [31] to 28 years [33].236 
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Table 1. Characteristic of included studies.                                                                                                                                                                                                             237 
Study is lead author and year of publication. Type: CT=controlled trial, RCT=randomised controlled trial. Diagnosis refers to the specific criteria that the researchers used to 238 
confirm PCOS diagnosis: Rotterdam = European Society for Human Reproductive and Embryology/American Society for Reproductive Medicine (2003). N = number of 239 
participants randomised into each arm of the study. BMI = mean body mass index (kg/m
2
) of participants in each arm at study entry. Duration, frequency, session length, 240 
mode and intensity refer to intervention characteristics. HRR = heart rate reserve, VO2 max = maximum oxygen update, LDL-C = low-density lipoprotein cholesterol, HDL-241 
C = high-density lipoprotein cholesterol, TC = total cholesterol, TG = triglycerides, WC = waist circumference, WHR = waist-to-hip ratio, TT = total testosterone, SHBG = 242 
sex hormone-binding globulin, HOMA-IR = homeostatic assessment of insulin resistance, SBP = systolic blood pressure, DBP = diastolic blood pressure, CRP = C-reactive 243 
protein.  α = statistically significant.244 
Study Type Diagnosis Exercisers Controls Duration Frequency 
Session 
Length 
Mode Intensity 
Outcomes 
Reported 
Significant 
Improvement 
Between 
Groups
α
 
Giallauria 
et al. 2008 
[30] 
CT Rotterdam 
N=62   
BMI=29.2 
kg/m
2
 
N=62   
BMI=29.5 
kg/m
2
 
3 months 3/week 30 min 
Bicycle 
ergometer 
60-70% of 
VO2 max 
LDL-C, HDL-C, 
TC, TG, Fasting 
Glucose, WHR, 
TT, SHBG, CRP, 
SBP, DBP 
WHR* and 
CRP* 
Sprung et 
al. 2013 
[32] 
CT Rotterdam 
N=10   
BMI=31 
kg/m
2
 
N=7   
BMI=35 
kg/m
2
 
16 weeks 
3/week for 
11 weeks 
5/week for 
5 weeks 
30 min 
for 11 
weeks, 
45 min 
for 5 
weeks 
Participant 
preference 
30% HRR 
for 11 
weeks, 
60% HRR 
for 5 
weeks 
LDL-C, HDL-C, 
TC, TG, Fasting 
Glucose, WC, TT, 
SHBG. HOMA-IR 
TC** and 
LDL-C** 
Vigorito et 
al. 2007 
[31] 
RCT Rotterdam 
N=45   
BMI=29.3 
kg/m
2
 
N=45   
BMI=29.4 
kg/m
2
 
3 months 3/week 30 min 
Bicycle 
ergometer 
60-70% 
VO2 max 
LDL-C, HDL-C, 
TC, TG, Fasting 
Glucose, WC, 
WHR, TT, 
HOMA-IR, SBP, 
DBP, CRP 
WC, WHR 
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Intervention Characteristics 245 
The exercise interventions duration in two studies were three months [31, 32], one was 16 246 
weeks [33]. All of the studies had an exercise frequency of three times per week [31, 32, 33]. 247 
One study began with three sessions per week for 11 weeks and then progressed to five 248 
sessions per week for five weeks [33]. Exercise intensity was determined by a percentage of 249 
VO2max [31, 32] or heart rate reserve (HRR) [33]. All were aerobic exercise interventions. 250 
Session length was 30 minutes in all three studies [31, 32, 33] increasing to 45 minutes after 251 
11 weeks in one [33]. Two studies were performed on a bicycle ergometer [31, 32], and one 252 
was performed on a stationary cycle, treadmill or elliptical machine according to participant 253 
preference [33].  254 
All three studies reported that all participants completed the study protocol [31, 32, 33]. All 255 
studies reported a mean adherence of ≥80%. All studies included women of reproductive age 256 
with a confirmed PCOS diagnosis. All studies specifically mentioned exclusion of 257 
participants who were taking OCP, metformin, or other hormonal, anti-androgen or 258 
carbohydrate metabolism modification drugs. All studies also specifically mentioned the 259 
exclusion of other conditions that could promote hyperandrogenism, such as Cushing’s 260 
Syndrome and congenital adrenal hyperplasia. All studies excluded those with thyroid 261 
dysfunction, diabetes, cardiovascular disease or other renal or hepatic diseases. Only one 262 
study confirmed exclusion of smokers and the exclusion or participants who undertook 263 
regular exercise [33]. Two studies did not specify a formal sample size calculation [31, 32] 264 
and another based this on an outcome of flow-mediated dilation [33]. 265 
 266 
Risk of Bias in Included Studies 267 
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The authors’ judgements about each risk of bias category are presented as percentages across 268 
all included studies in Fig 2. A summary of the authors’ judgements of each risk of bias item 269 
for each included study are presented in Fig 3. Further information outlining how each 270 
judgement was reached for each category in each included study is available in Online 271 
Resource 2. 272 
Online Resource 2. How each judgement was reached for each category in each included 273 
study. 274 
Fig 2 Risk of bias graph 275 
Review authors' judgements about each risk of bias item presented as percentages across all included 276 
studies 277 
 278 
Fig 3 Risk of bias summary 279 
Review authors' judgements about each risk of bias item for each included study 280 
Two studies (66.6%) were judged to have a high risk of selection bias because participants 281 
were allocated to groups based on their own choice [32, 33] and one (33.3%) was judged to 282 
have an unclear risk of selection bias because the authors did not report a method for 283 
randomisation or allocation concealment [31]. 284 
Performance bias was excluded from the assessment as all the studies included supervised 285 
exercise sessions so it is impossible to blind participants to this type of intervention while 286 
promoting exercise behaviour. Two studies (66.6%) were judged to have a low risk of 287 
detection bias because the blinding of outcome assessment was ensured, or the outcome 288 
measurement was not likely to be influenced by lack of blinding [31, 32]. The remaining 289 
study was judged to have an unclear risk of detection bias because the authors did not address 290 
this outcome. All studies were judged to have a low risk of attrition bias either due to zero 291 
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reported attrition rate, and all were judged to have an unclear risk of reporting bias because 292 
prospective protocols could not be located [31, 32, 33]. Additionally, we assessed whether of 293 
adherence (reported as <80%) may have presented a high risk of ‘other sources of bias’, and 294 
all were judged to be at a low risk [31, 32, 33]. 295 
Reporting of Outcomes 296 
All three studies reported on outcomes relating to lipid profile (such as HDL-C, LDL-C, TC 297 
and TG) but no studies reported oxidised LDL. All studies included either WC or WHR. Two 298 
studies reported fasting blood glucose and HOMA-IR measures [31, 33], and one reported 299 
just fasting blood glucose [32]. On androgen profile, all three studies reported total 300 
testosterone [31, 32, 33] and two reported sex hormone binding globulin (SHBG) in addition 301 
[32, 33]. Two studies reported systolic blood pressure (SBP) and diastolic blood pressure 302 
(DBP) [31, 32]. Only two studies reported inflammation markers and both of those reported 303 
C-reactive protein (CRP) [31, 32]. 304 
Effects of Exercise Versus Control 305 
Following our study inclusion criteria, only three studies could be included in the meta-306 
analysis. As such, subgroup analyses of exercise intensity, type and frequency were not 307 
performed. Subgroup analysis for intervention duration may have been possible, but given 308 
there would be two studies in one category and one in the other, it was deemed to be 309 
uninformative and potentially misleading [34]. Effect estimates, 95% CI and I
2
 values are 310 
listed in table 3 for each outcome.  311 
 312 
Table 3. Mean difference, 95% CI, P and I
2
 value for each outcome analysed. 313 
 314 
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N = number of participants. MD = Mean difference. LDL-C = low-density lipoprotein cholesterol, HDL-C = 315 
high-density lipoprotein cholesterol, TC = total cholesterol, TG = triglycerides, WC = waist circumference, 316 
WHR = waist-to-hip ratio, TT = total testosterone, SHBG = sex hormone-binding globulin, HOMA-IR = 317 
homeostatic assessment of insulin resistance, SBP = systolic blood pressure, DBP = diastolic blood pressure, 318 
CRP = C-reactive protein. 319 
 320 
Additionally, free testosterone measures were not available. Total testosterone measures 321 
indicated that the mean values for participants (231) in the studies eligible for meta-analysis 322 
were hyper-androgenemic, based on total testosterone (TT) concentrations of >2.0nmol/L 323 
[35, 36, 37], therefore subgroup-analysis of androgen profile could not be conducted.  324 
Primary Outcomes 325 
Blood lipids: 326 
All three studies (231 participants) in the meta-analysis assessed changes in LDL-C, HDL-C, 327 
TC and TG (231 participants). We observed no effect of exercise versus control on LDL-C, 328 
HDL-C or TG. We found a statistical effect of exercise on TC versus control (-4.70 mg/dl, 329 
95% CI -9.24, -0.32, I
2
 = 14%). When the study with a small sample size was removed [33], 330 
the effect was no longer statistically significant.  331 
Outcome Studies N MD Lower Upper P I
2  
(%) 
HDL-C (mg/dL) 3 231 -2.97 -6.62 0.68 0.11 0 
LDL-C (mg/dL) 3 231 -4.10 -13.32 5.22 0.39 42 
TC (mg/dL) 3 231 -4.78 -9.24 -0.32 0.04 14 
TG (mg/dL) 2 214 1.55 -4.66 7.76 0.63 0 
Fasting Glucose (mg/dL) 2 214 -1.75 -3.46 -0.04 0.04 0 
WC (cm) 2 107 -1.97 -3.35 -0.59 0.005 0 
WHR 2 214 -0.05 -0.08 -0.02 0.0003 0 
TT (nmol/L) 3 231 -0.20 -0.38 -0.02 0.03 47 
SHBG (nmol/L) 2 141 4.05 1.79 6.31 0.0004 0 
CRP (mg/L) 2 214 -0.34 -0.54 -0.15 0.0006 0 
SBP (rest) (mmHg) 2 214 -4.40 -7.13 -1.66 0.002 0 
DBP (rest) (mmHg) 2 214 -0.80 -1.96 0.37 0.18 0 
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Of the three studies in the analysis, one reported a significant decrease in LDL-C (-0.7 332 
mmol/L, 95% CI -1.1 to -0.3, P=0.001) and TC (-0.20 mmol/L, 95% CI -0.28 to -0.04, 333 
P=0.01) when compared to the control group [33]. 334 
 335 
Fasting Blood Glucose: 336 
Data from the three studies (231 participants) pooled in the meta-analysis showed a 337 
significant favourable effect of exercise on fasting glucose concentrations versus controls (-338 
1.75 mg/dL, 95% CI -3.45, -0.5, I
2 
=0%). When the study with a small sample size was 339 
removed [33], the effect remained significant (-1.75 mg/dL, 95% CI -3.46, -0.4, 214 340 
participants, I
2 
=0%).  341 
 342 
Measures of Abdominal Obesity: 343 
Two studies (107 participants) were pooled in the meta-analysis to assess changes to WC and 344 
WHR. A statistical favourable effect of exercise on WC (-1.97 cm, 95% CI -3.35, -0.59, I
2 345 
=0%) and a small but statistical favourable effect of exercise on WHR (-0.05, 95% CI -0.09, -346 
0.01, I
2 
=0%) compared to the control group was observed.  347 
One study reported a significant decrease in WC (P <0.01) and WHR (P <0.05) in the 348 
exercise group when compared to the control group [31]. One other reported significant 349 
decreases in WHR (P <0.05) in the exercise group compared to control [32].  350 
 351 
Blood Pressure: 352 
Two studies (214 participants) were pooled in the meta-analysis to assess changes in SBP and 353 
DBP at rest. The results indicated a statistical favourable effect of exercise on SBP in 354 
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comparison to controls (-4.40 mmHg, 95% CI -7.13, -1.66, I
2 
=0%) but no effect was 355 
observed for DBP. 356 
Of the two studies reporting SBP and DBP, one did not note any statistical effect of exercise 357 
on SBP or DBP in comparison to controls [32]. The other study [31] reported a significant (P 358 
< 0.01) decrease in SBP after the exercise intervention, but this was not significant in 359 
comparison to the control group. 360 
 361 
C-Reactive Protein: 362 
Two studies (114 participants) included in the meta-analysis recorded changes in CRP. The 363 
authors observed a small but statistical favourable effect of exercise on CRP compared to 364 
controls (-0.34 mg/l, 95% CI -0.54, -0.14, I
2 
=0%). Both studies had a sample size >30.  365 
Of the two studies one reported significant improvement after exercise only [31] and the 366 
other found significant improvement after exercise and between-groups [32]. Both studies 367 
were ≥12 weeks in duration, with sessions of 30 minutes on a bicycle ergometer. 368 
 369 
Secondary Outcomes 370 
Total Testosterone and Sex Hormone Binding Globulin: 371 
Three studies (231 participants) were pooled to assess changes in TT. The authors found a 372 
significant favourable effect of exercise on TT compared to controls, although moderate 373 
heterogeneity was noted (-0.20 nmol/l, 95% CI -0.38, -0.02, I
2 
=47%). Removal of the study 374 
with a small sample size [33] mitigated I
2  
to 35% and increased the statistical effect estimate 375 
(-0.24 nmol/l, 95% CI -0.43, -0.05, 114 participants). The same result was also observed 376 
when removing the study with the highest risk of bias [33]. 377 
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Only two of the studies reporting TT also reported changes to SHBG (114 participants). The 378 
meta-analysis indicated a favourable effect of exercise on SHBG concentrations (4.10, 95% 379 
CI 1.79, 6.31, I
2 
=0%). However, of note, both studies had a high risk of bias in two domains. 380 
 381 
Homeostatic Model Assessment of Insulin Resistance 382 
Only one study eligible for meta-analysis reported HOMA-IR and as such pooled analysis 383 
could not be conducted. No studies reported any significant improvement in HOMA-IR after 384 
exercise. 385 
Figures 4 to 15 show the comparisons for each outcome and subsequent forest plot. 386 
Fig 4 Forest plot of comparison: 1 – all interventions, outcome: 1.1 – HDL-C (mg/dL) 387 
Fig 5 Forest plot of comparison: 1 – all interventions, outcome: 1.1 – LDL-C (mg/dL) 388 
Fig 6 Forest plot of comparison: 1 – all interventions, outcome: 1.3 – TC (mg/dL) 389 
Fig 7 Forest plot of comparison: 1 – all interventions, outcome: 1.4 – TG (mg/dL) 390 
Fig 8 Forest plot of comparison: 1 – all interventions, outcome: 1.5 – Fasting blood glucose 391 
(mg/dL) 392 
Fig 9 Forest plot of comparison: 1 – all interventions, outcome: 1.6 – Waist circumference 393 
(cm) 394 
Fig 10 Forest plot of comparison: 1 – all interventions, outcome: 1.7 – Waist-to-hip ratio 395 
Fig 11 Forest plot of comparison: 1 – all interventions, outcome: 1.8 – Total testosterone 396 
(nmol/L) 397 
Fig 12 Forest plot of comparison: 1 – all interventions, outcome: 1.9 – Sex hormone-binding 398 
globulin (nmol/L) 399 
Fig 13 Forest plot of comparison: 1 – all interventions, outcome: 1.10 – C-reactive protein 400 
(mg/L) 401 
Fig 14 Forest plot of comparison: 1 – all interventions, outcome: 1.11 – Systolic blood 402 
pressure (rest) (mmHg) 403 
Fig 15 Forest plot of comparison: 1 – all interventions, outcome: 1.12 – Diastolic blood 404 
pressure (rest) (mmHg) 405 
 406 
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Quality of the Evidence 407 
Using GRADE, table 4 provides an evidence profile to reflect the extent of confidence that 408 
each estimate of effect from the pooled data-analysis is correct. Evidence has been 409 
downgraded for all outcomes due to the presence of serious study design limitations, 410 
including small sample size (≤30 participants), unclear or inappropriate randomisation or 411 
allocation procedures and non-randomised controlled trials. Subsequently, all evidence could 412 
only begin at a maximum of moderate quality.413 
21 
 
Table 4. GRADE evidence profile to assess confidence in effect estimates for each outcome. 414 
No of Studies 
(No. of 
participants) 
Quality Assessment Summary of Findings 
Study 
Limitations* 
Consistency Directness Precision 
Publication 
Bias 
P 
Value 
Effect  
(95% CI) 
Quality 
HDL-C                 
3 (231) 
Serious 
limitations (-1) 
No important 
inconsistency 
Direct Imprecision (-1)
a
 Unlikely 0.11 
-2.97  
(-6.62, 0.68) 
++, Low 
LDL-C                 
3 (231) 
Serious 
limitations (-1) 
No important 
inconsistency 
Direct Imprecision (-1)
a
 Unlikely 0.39 
-4.10  
(-13.43, 5.22) 
++, Low 
TC                 
3 (231) 
Serious 
limitations (-1) 
No important 
inconsistency 
Direct 
No important 
imprecision 
Unlikely 0.04 
-4.78  
(-9.24, -0.32) 
+++, 
Moderate 
WC                 
2 (107) 
Serious 
limitations (-1) 
No important 
inconsistency 
Direct 
No important 
imprecision 
Unlikely 0.005 
-1.97  
(-3.35, -0.59) 
+++, 
Moderate 
WHR                 
2 (107) 
Serious 
limitations (-1) 
No important 
inconsistency 
Direct 
No important 
imprecision 
Unlikely 0.0003 
-0.05  
(-0.08, -0.02) 
+++, 
Moderate 
Fasting Glucose                 
2 (214) 
Serious 
limitations (-1) 
No important 
inconsistency 
Direct 
No important 
imprecision 
Unlikely 0.04 
-1.75 
 (-3.46, -0.04) 
+++, 
Moderate 
TT                 
3 (231) 
Serious 
limitations (-1) 
Moderate 
Heterogeneity 
(-1)
b
 
Direct 
No important 
imprecision 
Unlikely 0.03 
-0.20  
(-0.38, -0.02) 
++, Low 
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SHBG 
2 (141) 
Serious 
limitations (-1) 
No important 
inconsistency 
Direct 
No important 
imprecision 
Unlikely 0.0004 
4.05  
(1.79, 6.31) 
+++, 
Moderate 
CRP                 
2 (214) 
Serious 
limitations (-1) 
No important 
inconsistency 
Direct 
No important 
imprecision 
Unlikely 0.0006 
-0.34  
(-0.54, -0.15) 
+++, 
Moderate 
SBP                 
2 (107) 
Serious 
limitations (-1) 
No important 
inconsistency 
Direct 
No important 
imprecision 
Unlikely 0.002 
-4.40  
(-7.13, -1.66) 
+++, 
Moderate 
DBP                 
2 (107) 
Serious 
limitations (-1) 
No important 
inconsistency 
Direct Imprecision (-1)
a
 Unlikely 0.18 
-0.80 
 (-1.96, 0.37) 
++, Low 
*unclear randomisation and allocation, non-randomised controlled trials, small sample size (<30). 
a  
=  confidence interval includes possible benefit in both directions. 
b
 =  I
2
 415 
47%. LDL-C = low-density lipoprotein cholesterol, HDL-C = high-density lipoprotein cholesterol, TC = total cholesterol, TG = triglycerides, WC = waist circumference, 416 
WHR = waist-to-hip ratio, TT = total testosterone, SHBG = sex hormone-binding globulin, HOMA-IR = homeostatic assessment of insulin resistance, SBP = systolic blood 417 
pressure, DBP = diastolic blood pressure, CRP = C-reactive protein. 418 
 419 
 420 
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Moderate heterogeneity was observed for only one outcome. Also, there was no important 421 
inconsistency of mean post-intervention values in most of the analyses. No outcomes were 422 
downgraded for indirectness, because all studies directly compared an exercise intervention 423 
versus usual care or control, with explicit exclusions of confounding medications. Where CI 424 
were wide or indicated possible benefit in both directions, evidence was downgraded due to 425 
imprecision and uncertainty of results. Publication bias of all outcomes was considered 426 
unlikely, since the authors conducted a thorough and comprehensive search of relevant 427 
databases, and no studies eligible for analysis declared any conflict of interest or funding 428 
sources that may have influenced publication. 429 
DISCUSSION 430 
This systematic review and meta-analysis identified three studies, including 231 participants 431 
with PCOS, that isolated and examined the effect of structured, supervised exercise on 432 
cardiometabolic outcomes in PCOS. Various recently published reviews have examined the 433 
effects of exercise and/or lifestyle modification on facets of PCOS [17, 38, 39, 40]. To the 434 
authors’ knowledge, this is the only recent review that has aimed to isolate the effects of 435 
exercise alone in comparison with control/standard care, without the inclusion of dietary, 436 
pharmacological or behavioural modification programmes.  437 
Summary of Main Findings 438 
Analysis of pooled data indicated, in the comparison of exercise and control, statistical 439 
favourable effects of exercise on TC, fasting glucose, WC, WHR, SBP, CRP, TT and SHBG 440 
using post-intervention scores. This supports the role of exercise as a treatment in the 441 
improvement of several cardiovascular risk factors in PCOS, including abdominal adiposity, 442 
insulin sensitivity, endothelial dysfunction and androgen profile. 443 
 444 
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Primary Outcomes 445 
The authors found a statistically-significant effect of exercise was observed on TC versus 446 
control (-4.70 mg/dl, 95% CI -9.24, -0.32, I
2
 = 14%), P = 0.04, but meta-analysis revealed no 447 
other significant changes to lipid profile in PCOS women. Other reviews have produced 448 
inconsistent results; a comprehensive, qualitative review [17] mostly found no significant 449 
effects of exercise only (without a dietary component) on lipid profile in PCOS, and those 450 
studies reporting significant improvements in TC involved a combined dietary and exercise 451 
component. Conversely, a recent review [38] noted a statistical effect of exercise on TC 452 
concentrations in PCOS in a pooled meta-analysis of just two studies (-0.09 mmol/L, 95% CI 453 
-0.10, -0.07), though it is not clear if this was based on exercise versus control only. 454 
Subsequently, sensitivity analysis rendered the pooled effect estimate non-significant. 455 
Additionally, since TC is the sum of LDL-C and HDL-C, the clinical relevance of this 456 
measure may be misleading, since LDL-C and HDL-C have contrasting roles within the 457 
vascular system and a change to either would affect the measure of TC [41]. TC:HDL  458 
appears to be a better predictor of cardiovascular risk than TC or LDL-C [42, 43]. 459 
Despite these results, exercise has been shown to have a positive effect on HDL-C and TG in 460 
healthy populations and those presenting with metabolic syndrome [44, 45, 46] with the latter 461 
sharing some cardiovascular risk factors with PCOS. This discrepancy may be due to the 462 
intervention characteristics shared by the three included studies (3/week, 30 minute-session). 463 
It has been reported that that changes to HDL-C and TG are more likely with an energy 464 
expenditure of 1200kcal/week [45]; these interventions may be unlikely to produce this 465 
output at lower intensities. Additionally, a 2004 review [44] indicates that interventions 466 
should be longer in duration (>20 weeks) to induce positive changes to HDL-C and TG in 467 
people with metabolic syndrome. 468 
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Pooled analysis of post-intervention values indicated a significant effect estimate of exercise 469 
versus control on fasting glucose concentrations (-1.75 mg/dl, 95% CI -3.45, -0.5, I
2 
=0%), P 470 
= 0.04. This effect remained significant after sensitivity analysis. This finding is in line with a 471 
recent review that indicated a statistically significant effect estimate of lifestyle modification 472 
versus minimal intervention on fasting blood glucose in PCOS (−2.3 mg/dL, 95% CI, −4.5 to 473 
−0.1, I2 = 72%) P = 0.04 [39]. However, statistical heterogeneity was noted, and exercise and 474 
dietary/behavioural modification were combined under ‘lifestyle intervention’. Two other 475 
reviews [38, 40] found no significant effects of lifestyle or exercise interventions on fasting 476 
blood glucose in PCOS. Despite this, various studies have demonstrated that aerobic exercise 477 
training enhances glucose disposal rate in women with PCOS [12, 47]. The mean fasting 478 
blood glucose range for the three studies in the pooled analysis was 84.6-95.6 mg/dL, which 479 
are all considered to be in the normal range of <100 mg/dL [48]. This is not unusual, because 480 
women with PCOS can maintain normal fasting glucose at the expense of increased insulin 481 
secretion [36]. Nevertheless, it is difficult to assess the clinical relevance of this outcome 482 
without comparative data on insulin sensitivity.  483 
We noted a statistically-favourable effect of exercise versus control on WC (-1.97 cm, 95% 484 
CI -3.35, -0.59, I
2 
=0%), P = 0.005, and WHR (-0.05, 95% CI -0.09, -0.01, I
2 
=0), P = 0.003, 485 
in two studies. This is in agreement with two other reviews [38, 40], although one combined 486 
exercise and dietary modification under lifestyle intervention [40]. WC and WHR have been 487 
shown to be, in some cases, a better indicator of health risk than BMI [49] because they 488 
measure abdominal obesity, a condition strongly associated with cardiovascular risk factors 489 
[50]. A decrease in WC and WHR has also been associated with improvements in glucose 490 
metabolism [51]. 491 
The authors observed that exercise had a statistically-significant effect on SBP in comparison 492 
to control (4.40 mmHg, 95% CI -7.13, -1.66, I
2 
=0%), P = 0.0003. This has been observed 493 
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after lifestyle intervention in PCOS in another review (-5.01 mmHg, 95% CI -6.63, -3.39, P < 494 
0.05, I
2 
=0%) [38]. A meta-analysis of RCTs [52] has indicated that aerobic exercise training 495 
produces a small but statistical improvement in blood pressure, even in the absence of weight 496 
loss, in normotensive adults. Blood pressure values among this population have been 497 
inversely associated with insulin sensitivity [44]. The mean data from the meta-analysis 498 
indicates that participants were normotensive (≤120 mmHg). We observed improvements of 499 
WC and WHR, shown to be associated with insulin sensitivity in PCOS [53]. As such, 500 
improvement in insulin regulation is a plausible explanation for several of the observed effect 501 
estimates. 502 
We observed a favourable statistical effect of exercise on CRP versus control (-0.34 mg/l, 503 
95% CI -0.54, -0.14, I
2 
=0%) P < 0.001. This finding is in agreement with another review that 504 
found favourable effects of lifestyle modification versus usual care (-0.47 mmol/L, 95% CI -505 
0.80, -0.15, P = 0.004, I
2 
=0%). Indeed, PCOS has been linked to an inflammatory state 506 
characterised by increased levels of CRP [19, 54]. However, the clinical relevance of this 507 
finding may be tenuous; the mean CRP range for the studies in the pooled analysis was 1.54-508 
1.92 mg/L, which are considered to be within the normal range [55] and as such this may not 509 
indicate an inflammatory state in the participants. Also, the effect may not be reproduced in 510 
populations with a higher than normal value. 511 
 512 
Secondary Outcomes 513 
Pooled data analysis indicated a statistical favourable effect of exercise versus control on 514 
TT(-0.20 nmol/L, 95% CI -0.38, -0.02, I
2 
=47%) P = 0.03, and SHBG (4.05, 95% CI 1.79, 515 
6.31, I
2 
=0%) P < 0.001. Both outcomes were derived from at least one study with a high risk 516 
of bias for randomisation and allocation procedures. Nevertheless, a previous review has 517 
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noted a statistical lowering of fasting insulin levels in the exercise group compared to the 518 
control group in PCOS (-0.95 μU/mL, 95% CI -1.48, -0.43, P < 0.05, I2 =0%) [38]. 519 
Additionally, a qualitative systematic review found evidence for improved insulin sensitivity 520 
following exercise in PCOS [17]. An improvement in insulin sensitivity following exercise 521 
could therefore be an explanation for both reduced TT and increased SHBG; 522 
hyperinsulinemia causes an increase in free androgen plasmatic levels both through the 523 
stimulation of ovarian androgen synthesis, and by suppressing hepatic production of SHBG 524 
[56]. We were not able to perform a meta-analysis on free testosterone; caution is advised 525 
when measuring TT alone, because women with PCOS can have TT in the normal range but 526 
have high concentrations of free and bioavailable testosterone due to lower concentrations of 527 
SHBG [36]. However, the data indicate that the participants in the meta-analysis had low 528 
enough SHBG concentrations (<30 nmol/L), even post-intervention, to indicate 529 
hyperandrogenism [36]. This provides further plausibility to the explanation that exercise 530 
may have mitigated insulin hypersecretion, thereby increasing hepatic production of SHBG 531 
and reducing ovarian androgen synthesis to the effect of reduced TT. 532 
 533 
Overall Completeness and Applicability of Evidence 534 
One study in the analysis was an RCT and two were non-RCT. This limits the overall 535 
applicability of the evidence, particularly where participants were allocated to groups based 536 
on preference. Although the studies specified no statistical differences in baseline 537 
characteristics, it is possible that the adherence and attrition rates are not truly reflective of 538 
those that would be observed in gold-standard RCTs. 539 
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Only one study specified formal sample size calculations, and this study had a small sample 540 
size (17 participants). In samples of this size, variance in scores is likely to affect statistical 541 
significance and applicability to the general PCOS population is limited.  542 
Sub-group analysis based on androgen profile was not possible, because the studies included 543 
in the meta-analysis indicated that the mean TT concentration for all participants were high 544 
enough to constitute hyperandrogenemia. Typical cut-off values of TT for 545 
hyperandrogenemia are generally >2.1 nmol/L [36, 37] and post-intervention values for all 546 
participants in the meta-analysis (n=231) ranged from 2.1-2.5 nmol/L. The results of the 547 
meta-analysis may therefore have limited applicability to normo-androgenic phenotypes and 548 
differences in treatment responsiveness between phenotypes have not been highlighted.  549 
An important characteristic of the review was to only include trials where OCP was clearly 550 
excluded. The authors wanted to avoid the contamination of the data by the hormonal and 551 
metabolic changes associated with the OCP, particularly those with low or anti-androgenic 552 
properties, such as hepatic synthesis of SHBG that reduces free testosterone concentrations 553 
[57]. Additionally, in overweight or obese women with PCOS, research suggests that certain 554 
types of OCP containing desogestral or cyproterone acetate can aggravate insulin resistance 555 
and decrease glucose tolerance [58, 59, 60]. Because of the considerable variability in the 556 
presentation of clinical and metabolic symptoms of PCOS, including varying levels of 557 
glucose tolerance, hyperandrogenism and insulin sensitivity, as well as the variation in the 558 
types and metabolic effects of OCPs used to manage PCOS symptoms, we excluded those 559 
participants taking OCP to reduce the effects of inter-person variability in the meta-analysis. 560 
PCOS is the most common cause of infertility [61]. It is estimated that 40% of women with 561 
PCOS are affected by infertility or difficulty conceiving [62]. As a result, approximately up 562 
to 95% of anovulatory women seeking or receiving fertility treatment have PCOS [45]. 563 
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Therefore, although OCP may be a front-line management tool in PCOS in women not 564 
aiming to conceive [58], there exists a substantial proportion of women with PCOS that are 565 
not taking OCP, many of whom are encouraged to improve their health to increase chances of 566 
conception, indicating that the findings of this review have applicability to this subset of the 567 
population. 568 
Potential Biases in the Review Process and Limitations 569 
We restricted our eligibility criteria to articles published in the English language. 570 
Consequently, it is possible that additional information from trials that would have otherwise 571 
met the inclusion criteria may have been excluded. Also, trials were only eligible for 572 
inclusion if the full-text could be obtained; subsequently at least one eligible trial could not 573 
be included because the abstract was for a conference and the full-text had not been 574 
published. These factors may contribute to publication bias. Due to a lack of trials in the 575 
meta-analysis, funnel plots could not be utilised for the analysis of publication bias. 576 
Some difficulty in study selection occurred due to a lack of trials that explicitly excluded the 577 
use of OCP and other hormonal or metabolism-altering drugs. The authors could only select 578 
studies if this was specifically excluded, and as such some studies may have been excluded 579 
for not providing such a statement. Similarly, at least one gold-standard RCT was excluded 580 
due to the use of non-normally distributed data and non-parametric tests. These data could 581 
have influenced findings if they could be synthesised for meta-analysis and thus had to be 582 
excluded. 583 
Many of the outcomes were based on studies with serious limitations, including a high risk of 584 
selection bias, and small magnitude effect estimates. This limits the quality of the evidence, 585 
despite the directness and consistency of the evidence for most outcomes. As noted, the 586 
generalisability may also be limited by the high occurrence and selection bias, and 587 
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particularly by study designs which allowed participant allocation based on preference rather 588 
than true randomisation. 589 
Future Research Recommendations 590 
Most studies featured moderate-intensity aerobic interventions, with less emphasis on 591 
resistance training in the literature, therefore different types of exercise intervention could not 592 
be compared. Current physical activity guidelines recommend that adults undertake activity 593 
to improve muscle strength on at least two days a week [63]. As such, a greater emphasis 594 
should be placed on the inclusion of resistance exercises in exercise interventions to identify 595 
additional benefits to cardiometabolic health in PCOS. Future consideration could also be 596 
given to tools for self-reporting physical activity, such as the Global Physical Activity 597 
Questionnaire, as well as interventional studies. 598 
 599 
CONCLUSIONS  600 
The results of the pooled data analysis indicated that moderate aerobic exercise interventions 601 
≥3 months in duration, with a frequency of 3/week for at least 30-minute-long sessions, may 602 
have favourable effects on various cardiometabolic risk factors including TC, fasting blood 603 
glucose, WC, WHR, SBP and CRP in women with PCOS. Additionally, we observed that if 604 
participants have TT and SHBG concentrations outside of normal ranges, this type of 605 
intervention could improve androgen profile in comparison to usual care. 606 
As indicated by our analysis of the quality of the evidence, various outcomes were judged to 607 
be of a moderate quality, with statistically significant, precise effect estimates. Nonetheless, 608 
results should be interpreted with caution due to the presence of serious methodological 609 
limitations including a lack of gold-standard RCTs and a high risk of selection bias. 610 
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We conducted a thorough search of nine databases from inception to present but were only 611 
able to find three eligible studies that isolated the effects of exercise alone versus usual care 612 
that explicitly excluded the use of OCP and other hormonal or metabolism-altering drugs. 613 
Only one of these was a gold-standard RCT, albeit judged to have an unclear risk of selection 614 
bias due to unclear randomisation or allocation procedures. This review highlights the 615 
limitations of the available literature. More gold-standard RCTs that can make direct 616 
comparisons between treatment options for PCOS, including exercise, pharmacological, 617 
behavioural and dietary interventions could provide greater precision for future 618 
recommendations of treatment options, including the efficacy of exercise in comparison to 619 
other treatments. However, the authors acknowledge that this may have limited applicability 620 
to the general population; often, patients with PCOS may undertake combined interventions 621 
to get the best results, and studies designed in this manner may provide greater applicability 622 
in that regard. 623 
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